These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20185312)

  • 21. Design, Synthesis, and Biological Evaluations of Novel Thiazolo[4,5-d]pyrimidine Corticotropin Releasing Factor (CRF) Receptor Antagonists as Potential Treatments for Stress Related Disorders and Congenital Adrenal Hyperplasia (CAH).
    Islam MR; Markatos C; Pirmettis I; Papadopoulos M; Karageorgos V; Liapakis G; Fahmy H
    Molecules; 2024 Aug; 29(15):. PubMed ID: 39125051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of CRF1R binding affinity of 2-(2,4,6-trichlorophenyl)-4-trifluoromethyl-5-aminomethylthiazoles through rapid and selective parallel synthesis.
    Zuev D; Michne JA; Pin SS; Zhang J; Taber MT; Dubowchik GM
    Bioorg Med Chem Lett; 2005 Jan; 15(2):431-4. PubMed ID: 15603967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.
    Arvanitis AG; Gilligan PJ; Chorvat RJ; Cheeseman RS; Christos TE; Bakthavatchalam R; Beck JP; Cocuzza AJ; Hobbs FW; Wilde RG; Arnold C; Chidester D; Curry M; He L; Hollis A; Klaczkiewicz J; Krenitsky PJ; Rescinito JP; Scholfield E; Culp S; De Souza EB; Fitzgerald L; Grigoriadis D; Tam SW; Shen HL
    J Med Chem; 1999 Mar; 42(5):805-18. PubMed ID: 10072679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.
    Chen YL; Mansbach RS; Winter SM; Brooks E; Collins J; Corman ML; Dunaiskis AR; Faraci WS; Gallaschun RJ; Schmidt A; Schulz DW
    J Med Chem; 1997 May; 40(11):1749-54. PubMed ID: 9171885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists.
    Zuev D; Vrudhula VM; Michne JA; Dasgupta B; Pin SS; Huang XS; Wu D; Gao Q; Zhang J; Taber MT; Macor JE; Dubowchik GM
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3669-74. PubMed ID: 20471832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists.
    Kojima T; Mochizuki M; Takai T; Hoashi Y; Morimoto S; Seto M; Nakamura M; Kobayashi K; Sako Y; Tanaka M; Kanzaki N; Kosugi Y; Yano T; Aso K
    Bioorg Med Chem; 2018 May; 26(9):2229-2250. PubMed ID: 29459145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
    Jurczyk S; Kołaczkowski M; Maryniak E; Zajdel P; Pawłowski M; Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E; Bojarski AJ; Charakchieva-Minol S; Duszyńska B; Nowak G; Maciag D
    J Med Chem; 2004 May; 47(10):2659-66. PubMed ID: 15115407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
    Ye Y; Liao Q; Wei J; Gao Q
    Neurochem Int; 2010 Jan; 56(1):107-17. PubMed ID: 19782115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective antagonism of CRF1 receptor by a substituted pyrimidine.
    Sakellaris S; Matsoukas MT; Karageorgos V; Poulaki S; Kuppast B; Margioris A; Venihaki M; Fahmy H; Liapakis G
    Hormones (Athens); 2019 Jun; 18(2):215-221. PubMed ID: 30980254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.
    Chorvat RJ; Bakthavatchalam R; Beck JP; Gilligan PJ; Wilde RG; Cocuzza AJ; Hobbs FW; Cheeseman RS; Curry M; Rescinito JP; Krenitsky P; Chidester D; Yarem JA; Klaczkiewicz JD; Hodge CN; Aldrich PE; Wasserman ZR; Fernandez CH; Zaczek R; Fitzgerald LW; Huang SM; Shen HL; Wong YN; Chien BM; Arvanitis A
    J Med Chem; 1999 Mar; 42(5):833-48. PubMed ID: 10072681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heteroatom-linked indanylpyrazines are corticotropin releasing factor type-1 receptor antagonists.
    Corbett JW; Rauckhorst MR; Qian F; Hoffman RL; Knauer CS; Fitzgerald LW
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6250-6. PubMed ID: 17888659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, molecular modeling and biological activity of methyl and thiomethyl substituted pyrimidines as corticotropin releasing hormone type 1 antagonists.
    McCluskey A; Keller PA; Morgan J; Garner J
    Org Biomol Chem; 2003 Oct; 1(19):3353-61. PubMed ID: 14584799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
    Nielsen DM; Carey GJ; Gold LH
    Eur J Pharmacol; 2004 Sep; 499(1-2):135-46. PubMed ID: 15363960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
    Nielsen DM
    Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corticotropin-releasing hormone modulators and depression.
    Holsboer F
    Curr Opin Investig Drugs; 2003 Jan; 4(1):46-50. PubMed ID: 12625028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
    Gilligan PJ; Clarke T; He L; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy JF; Ward K; Zeller K; Wong H; Bai S; Saye J; Grossman S; Zaczek R; Arneric SP; Hartig P; Robertson D; Trainor G
    J Med Chem; 2009 May; 52(9):3084-92. PubMed ID: 19361209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-arylaminothiazoles as high-affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy.
    Dubowchik GM; Michne JA; Zuev D; Schwartz W; Scola PM; James CA; Ruediger EH; Pin SS; Burris KD; Balanda LA; Gao Q; Wu D; Fung L; Fiedler T; Browman KE; Taber MT; Zhang J
    Bioorg Med Chem Lett; 2003 Nov; 13(22):3997-4000. PubMed ID: 14592493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and adenosine receptor binding studies of some novel triazolothienopyrimidines.
    Raghu Prasad M; Raghuram Rao A; Shanthan Rao P; Rajan KS; Meena S; Madhavi K
    Eur J Med Chem; 2008 Mar; 43(3):614-20. PubMed ID: 17602796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.
    Arborelius L; Skelton KH; Thrivikraman KV; Plotsky PM; Schulz DW; Owens MJ
    J Pharmacol Exp Ther; 2000 Aug; 294(2):588-97. PubMed ID: 10900236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and structure-activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists.
    Han X; Pin SS; Burris K; Fung LK; Huang S; Taber MT; Zhang J; Dubowchik GM
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4029-32. PubMed ID: 15982881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.